Post-transplant lymphoproliferative disorder of the adrenal gland after allogeneic hematopoietic stem cell transplantation: Report of two cases and literature review

Research output: Contribution to journalArticle

1 Citation (Scopus)


Post-transplant lymphoproliferative disorder (PTLD) is one of the life-threatening complications after hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT), and it is associated almost exclusively with Epstein-Barr virus (EBV). We herein report 2 cases of EBV-associated PTLD after allogeneic HSCT localized in the adrenal gland. Both patients developed adrenal tumor within 3 months after HSCT and were successfully treated with rituximab or tapering immunosuppressive agents. Both remained alive without recurrence. A literature review revealed 12 reported cases of PTLD involving the adrenal gland, but the adrenal gland was involved as one of the lesions of advanced-stage PTLD after SOT. To the best of our knowledge, this is the first report to show cases of isolated EBV-associated adrenal PTLD after HSCT. PTLD should be recognized as one of the causes of isolated adrenal tumor after HSCT.

Original languageEnglish
Pages (from-to)909-914
Number of pages6
JournalTransplant Infectious Disease
Issue number6
Publication statusPublished - 2015 Dec 1



  • Adrenal gland
  • Allogeneic hematopoietic stem cell transplantation
  • Epstein-Barr virus
  • Post-transplant lymphoproliferative disorder
  • Rituximab

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Cite this